COMMON STOCK PURCHASE WARRANTNymox Pharmaceutical Corp • May 6th, 2021 • In vitro & in vivo diagnostic substances
Company FiledMay 6th, 2021 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 30, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 6th, 2021 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMay 6th, 2021 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of April 28, 2021, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 6th, 2021 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances
Contract Type FiledMay 6th, 2021 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of April 28, 2021, by and between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
Re: Private Placement of Common Stock and Common Stock Purchase WarrantsNymox Pharmaceutical Corp • May 6th, 2021 • In vitro & in vivo diagnostic substances • New York
Company FiledMay 6th, 2021 Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares (the “Shares”) of the Company’s Common Stock, no par value per share (the “Common Stock”), and the common stock purchase warrants to purchase shares of Common Stock (together with the Common Stock, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein constitutes that the Placement Agent would have the powe